Global Ebola Virus Infection Drug Market 2019 Top Key Players Merck & Co., Inc, NewLink Genetics Corporation, Johnson & Johnson Private Limited , GlaxoSmithKline plc, Novavax, GeoVax, Mapp Biopharmaceutical, Arbutus Biopharma, Bavarian Nordic
Market Analysis: Global Ebola Virus Infection Drug MarketGlobal Ebola Virus Infection Drug Market is rising with a substantial CAGR in the forecasted period of 2019-2026. This rise in market can be attributed to the increasing number of Ebola virus infected patients , growing prevalence of Ebola virus infections, the lack of a reliable cure for Ebola virus infections and steady government support to Ebola research, developing Ebola drugs and vaccines.
The market analysis and insights covered in this Global Ebola Virus Infection Drug Market report presents key statistics on the market status of global and regional manufacturers and is an essential source of guidance which provides right direction to the companies and individuals interested in the industry.
By attaining an actionable market insight via this X Global Ebola Virus Infection Drug Market research report, sustainable and profitable business strategies can be built. Also, Global Ebola Virus Infection Drug Market report gives an in-depth knowledge on what the recent developments, products launches are, while also keeping the track for recent acquisitions, mergers, joint ventures and competitive research in the global market industry.
Request Free Sample Copy Report at @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-ebola-virus-infection-drug-market
Ebola Virus Infection Drug Industry Recovery from EVD depends on good supportive care and the patient’s immune response. Those who do recover develop antibodies that can last 10 years, possibly longer. It is not known if people who recover are immune for life or if they can later become infected with a different species of Ebola virus. Some survivors may have long-term complications, such as joint and vision problems.
Key Market Players: Global Ebola Virus Infection Drug Market
• Merck & Co., Inc,
• NewLink Genetics Corporation,
• Johnson & Johnson Private Limited ,
• GlaxoSmithKline plc,
• Novavax,
• GeoVax,
• Mapp Biopharmaceutical,
• Arbutus Biopharma,
• Bavarian Nordic ,
• Nanoviricides, INC,
• Sarepta Therapeutics,
• Chimerix, Biocryst Pharmaceuticals, INC,
• Hemispherx Biopharma, Inc,
• BioComo Incorporation,
• Peptineo,
• Bio-Excel,
• Geneone Life Sciences,
• IMV Inc, Etubics
Market Definition: Global Ebola Virus Infection Drug Market
Ebola virus infection is a serious fatal condition which is caused by the four different species of Ebola virus in humans and non-human primates. It causes hemorrhagic fever which leads to internal and external bleeding and affects multiple organs. A person with Ebola virus infection at initial stage experiences sore throat, muscular pain, headaches. Vomiting, rashes and diarrhea at later stages along with decreased function of kidney and liver. At this stage some patients begin to bleed internally as well as externally. This infection has about average 50.0% of high risk of deaths.
Market Drivers
• Increasing number of Ebola virus infected patients
• Growing prevalence of Ebola virus infections around the world
• Increasing awareness about the infection
• Lack of a reliable cure for Ebola virus infections
• Steady government support for Ebola research including development of Ebola drugs and vaccines
Market Restraints
• The unpredictable nature of Ebola has slow down research efforts
• Unavailability of effective treatment
• Lack of awareness among the patient and physician about chronic obstructive pulmonary disease treatment
Get Detailed TOC: @ https://databridgemarketresearch.com/toc/?dbmr=global-ebola-virus-infection-drug-market
Segmentation: Global Ebola Virus Infection Drug Market
By Strain Type
• Zaire
• Sudan
• Tai forest
• Bundibugyo virus
Novel Drug Type
• Zmapp
• Favipiravir
• GS-5734
• TKM-Ebola
• AVI-7537
Vaccine Type
• cad3-ZEBOV
• rvsv-ZEBOV
Route of Administration
• Oral
• Intravenous
• Others
By End Users
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Geography
• North America
o U.S.
o Canada
o Mexico
• South America
o Brazil
o Argentina
o Rest of South America
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Turkey
o Belgium
o Netherlands
o Switzerland
o Rest of Europe
• Asia-Pacific
o Japan
o China
o South Korea
o India
o Australia
o Singapore
o Thailand
o Malaysia
o Indonesia
o Philippines
o Rest of Asia-Pacific
• Middle East & Africa
o South Africa
o Egypt
o Saudi Arabia
o United Arab Emirates
o Israel
o Rest of Middle East & Africa
Key Developments in the Market:
• In March 2015, ChAd3-ZEBOV vaccine is developed by GlaxoSmithKline plc in collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID) is under phase II/III of clinical trial and shows 90.0% efficacy rate, and the safety of vaccine and placebo is high.
• In April 2015, VSV-EBOV vaccine is developed by NewLink Genetics and Merck & Co., Inc. in collaboration with the Public Health Agency of Canada is under phase III of clinical trial and currently in use and shows very high efficacy rate and the vaccine regimen appears to be well tolerated by adult volunteers.
Competitive Analysis: Global Ebola Virus Infection Drug Market
Global Ebola virus infection drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of ebola virus infection drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Reasons to Purchase this Report
• Current and future of global Ebola virus infection drug market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
• Regions/Countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Customization of the Report:
• All segmentation provided above in this report is represented at country level
• All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)
High points of the report
o CAGR values in the market for the forecast period
o Key trends in the market place
o Major players and brands
o Drivers and restrains of the market
o Competitive landscape
o Potential and niche segments/regions exhibiting promising growth
Want Full Report? Enquire here https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-ebola-virus-infection-drug-market
Contact:
Sopan Gedam
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Ebola Virus Infection Drug Market 2019 Top Key Players Merck & Co., Inc, NewLink Genetics Corporation, Johnson & Johnson Private Limited , GlaxoSmithKline plc, Novavax, GeoVax, Mapp Biopharmaceutical, Arbutus Biopharma, Bavarian Nordic here
News-ID: 1793087 • Views: …
More Releases from Data Bridge Market Research
Unveiling the Power: Radio Frequency Identification (RFID) Middleware in Modern …
Data Bridge Market Research analyses that the radio frequency identification (RFID) middleware market will exhibit a CAGR of 10.15% for the forecast period of 2022-2022 and is expected to reach the market value of USD 5.03 billion by 2029.
Radio Frequency Identification (RFID) refers to a wireless system comprised of two components tags and readers. The reader is a device that has one or more antennas that emit radio waves and…
Streamlining Service: Innovations in Hospitality Management Software
The hospitality management software market is expected to witness market growth at a rate of 8.37% in the forecast period of 2022 to 2029. Data Bridge Market Research report on hospitality management software market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market's growth. The rise in the adoption of the cloud-based hotel management software is…
SCARA Robot Market to Observe Highest Growth of USD 28,345.20 billion with an Ex …
Global Scara Robot Market study by Data Bridge Market Research provides details about the market dynamics affecting the Scara Robot market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.
A number of estimations and calculations have been included in the first class Scara Robot market report by assuming definite base year and the historic year. The…
Ammonium Sulfate Market to Observe Prominent CAGR of 3.85% by 2028, Size, Share, …
Data Bridge Market research has recently issued comprehensive industry research on Global Ammonium Sulfate Market which includes growth analysis, regional marketing, challenges, opportunities, and drivers analysed in the report. The market insights gained through this Ammonium Sulfate market research analysis report facilitates more defined understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently.
An analysis of competitors is conducted very well…
More Releases for Ebola
Ebola Virus Vaccine Market 2022 | Detailed Report
The Ebola Virus Vaccine research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market's key players. Furthermore, the report offers insightful market data and information about the Ebola…
Ebola Vaccine Market Opportunity Analysis, 2018-2026
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus…
Ebola Vaccine Market - Global Industry Insights, 2017-2025
Increasing number of Ebola cases in affected regions and new vaccine development for this are expected to be factors driving growth of the market
Increasing mortality rates due to Ebola is expected to be a major factor for growth of the market. According to World Health Organization, in January 2018, around 50% people infected with EVD, have died. African countries such as Siberia, Sierra Leone, Guinea, Democratic Republic of Congo, Senegal,…
Ebola Treatment Market Rugged Expansion Foreseen by 2024
Ebola viral infection was first observed in The Democratic Republic of Congo (named after a river called Zaire) in 1976. Ebola is a viral disease which frequently causes lethal haemorrhagic fever in humans. The harmful consequences of Ebola viral infection are that the viruses can be used as potential biological weapon. The symptoms of Ebola viral infection include sudden onset of fever, sore throat, headaches, extreme tiredness, vomiting, skin rash,…
Growing Trends in Ebola Drug and Vaccine Market
The rising threat of a global Ebola pandemic is the major driver for the global Ebola drug and vaccines market, according to a new report from Transparency Market Research. The report, titled ‘Ebola Drug and Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends & Forecasts 2016 – 2024,’ presents a solid outline of the historical development of the market, in addition to comprehensive information about the market’s present…
Ebola Virus Vaccine Market & Pipeline Insight
Ebola virus infection, which was previously called Ebola hemorrhagic fever was discovered in 1976. The infection caused due to ebola virus originates from four different strains of ebola virus. These viruses generally are known to affect non-human primates, and are transmitted from wild animals to the humans and among the latter, it is known to spread through human-to-human transmission. The natural hosts of ebola virus are Fruit bats, which…